Connect your AI

Roivant Sciences ROIV Total Liabilities

Total Liabilities at other companies

ModernaMRNA

$4.08B+54.7%

Immunovant, Inc.IMVT

$104.42M+51.8%

Bristol-Myers SquibbBMY

$66.37B-11.5%

RegenxbioRGNX

$320.81M+48.0%

CNT

Canton Strategic Holdings IncCNTN

$114.86M+4,539%

AmgenAMGN

——

Other financials

Income statement

Revenue$2.5M-66.7%

Operating income-$339.2M-23.6%

Net income-$265.9M-257%

EPS (diluted)-$0.38-265%

Balance sheet

Cash & equivalents$1.4B+1,411%

Total debt$107.4M+7.3%

Total equity$4.5B-3.4%

Total assets$5.7B+5.0%

Cash flow

Operating cash flow-$163.8M+5.1%

CapEx$1.3M+55.5%

Free cash flow-$165.1M+4.8%

Valuation

Market cap$25.25B+226%

Enterprise value$23.93B+209%

P/S3,056.5×+2,723×

Profitability

Operating margin-9,130.5%-13,995pp

Net margin-6,079.9%-6,193pp

FCF margin-9,183.5%-17,093pp

Returns & leverage

Return on equity-17.1%-17.7pp

Debt / equity0×0.0×

Current ratio18.4×-15.1×

Where this comes from

Reported directly by Roivant Sciences in its filing.

Tagged under the XBRL concept us-gaap:Liabilities.

The official record: Roivant Sciences’s 10-K, filed May 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about Roivant Sciences's total liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Roivant Sciences's total liabilities?: Roivant Sciences (ROIV) reported total liabilities of $416.28M in Q1 2026.
How has Roivant Sciences's total liabilities changed year-over-year?: Roivant Sciences's total liabilities increased by 66.7% year-over-year, from $249.74M to $416.28M.
What is the long-term trend for Roivant Sciences's total liabilities?: Over 5 years (2020 to 2025), Roivant Sciences's total liabilities has grown at a -4.6% compound annual growth rate (CAGR), from $527.69M to $416.28M.
What does total liabilities mean?: The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.